ArticleSisli Etfal Hastanesi tip bulteni2026
Baseline and Longitudinal Pan-Immune-Inflammation Value Compared with Other Inflammatory Indices in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort Study.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The pan-immune-inflammation value (PIV), calculated from neutrophil, platelet, monocyte, and lymphocyte counts, is a peripheral blood biomarker of systemic immune-inflammatory status. We evaluated the prognostic value of baseline PIV and its trajectory over the first six months of treatment for overall survival (OS) and progression-free survival (PFS) in patients receiving immune checkpoint inhibitors (ICIs) and benchmarked PIV against the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). Methods: We retrospectively analyzed 205 patients treated at a single tertiary center for non-small-cell lung cancer, renal cell carcinoma, melanoma, or other solid tumors who received an ICI (90.2% nivolumab). PIV was measured at baseline, month 3, and month 6. The outcome-independent median value (587.7) defined the PIV-low and PIV-high groups. Cox regression (per doubling of log2-transformed PIV), Kaplan-Meier analysis, 3- and 6-month landmark models, time-updated Cox models, and restricted cubic splines were used, with adjustment for age, sex, and tumor type. Discrimination was assessed using Harrell's C-index, 1000-resample bootstrap internal validation, and time-dependent area under the curve (AUC). Results: The median follow-up was 50.6 months; 168 deaths and 190 progression-or-death events occurred. Each doubling of baseline PIV was independently associated with worse OS (adjusted HR, 1.24; 95% confidence interval [CI], 1.14-1.36; p<0.001) and PFS (HR, 1.18; 95% CI, 1.09-1.28; p<0.001). Median OS was 11.96 vs. 5.62 months, and median PFS was 6.21 vs. 3.45 months, in the PIV-low vs. PIV-high groups (log-rank p<0.001 for both). Month-3 and month-6 absolute PIV values remained prognostic in landmark analyses, whereas the relative change in PIV from baseline to month 3 was not associated with either outcome. The association was approximately log-linear (nonlinearity p>0.05 for OS and PFS). PIV, NLR, PLR, and SII showed similar discrimination (adjusted C-index for OS: 0.650, 0.647, 0.633, and 0.652, respectively); PIV had the lowest Akaike information criterion (AIC) and Bayesian information criterion (BIC) values among the four indices. Conclusion: Baseline and on-treatment absolute PIV values, but not early relative changes in PIV, are independently associated with survival outcomes in patients receiving ICIs, with prognostic performance comparable to that of established inflammatory indices. PIV may serve as a simple, repeatable biomarker to support risk stratification during ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.